Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Tandem Diabetes (TNDM) to $23 from $17 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.